2023 Fen-Phen - Pulmonary Hypertension

Fen-Phen Lawyer, Cynthia K. Garrett, has been representing Pondimin & Redux pulmonary hypertension victims since 1998.  Accepting new Fen-Phen clients nationwide.  Fen-Phen lawsuits and claims are still being filed and paid. 

 Pulmonary hypertension is elevated blood pressures that affects the arteries in your lungs and the right side of your heart.   The condition requires on-going medical treatment.  The disease is potentially fatal if it cannot be effectively treated.  Pulmonary hypertension is characterized as primary or idiopathic when all known causes which can be ruled out have been ruled out.  ​

Known causes which must be ruled out before pulmonary hypertension is considered to be PPH / IPAH: 
Left-sided heart disease such as aortic or mitral valve disease, failure of the lower left chamber of the heart, inherited risks for PH, congenital heart defects including Eisenmenger syndrome (large hole between the two lower chambers of the heart), portal hypertension, scleroderma, lupus, HIV, cirrhosis, use of methamphetamines or cocaine, exposure to certain toxins, and lung diseases such as: COPD, emphysema, pulmonary fibrosis, interstitial fibrosis (such as silicosis, asbestosis, and granulomatous), significant sleep apnea, long-term exposure to high altitudes, and chronic blood clots in the lungs.  Other possible causes include: certain blood disorders, sarcoidosis, glycogen storage disease, and tumors pressing against pulmonary arteries. 

Pulmonary hypertension can lead to complications including: right-sided heart enlargement, heart failure, blood clots in the lungs, heart arrhythmia, and bleeding in the lungs.

Pulmonary hypertension requires on-going medical treatment.  The disease is potentially fatal if it cannot be effectively treated. 

 Fen-Phen is the common name of a weight loss protocol heavily marketed in the 1990's that included fenfluramine (Pondimin) or dexfenfluramine (Redux). Pondimin and Redux were shown to cause damage to the mitral and aortic heart valves; and a serious lung condition called primary pulmonary hypertension. 

Pondimin and Redux were withdrawn from the U.S. market in 1997.  This litigation only includes those who used Pondimin or Redux.  

 Fen Phen lawsuits are filed in Federal Court by those who took Pondimin or Redux, have been diagnosed with Primary Pulmonary Hypertension - which is also called Idiopathic Pulmonary Arterial Hypertension - and are now seeking financial compensation for their injuries.  If that person is deceased, a court-appointed personal representative may file the lawsuit on behalf of the deceased Fen Phen user's estate.  

 Fen Phen class action claims are filed with the AHP Settlement Trust - the trust established by court order to administer and pay claims associated with aortic or mitral valve injuries.  These claims seek financial compensation for the injured and their derivative beneficiaries.  If the injured Fen Phen user is deceased, a court-appointed personal representative may file the claim.